Literature DB >> 30122513

An integrated modelling methodology for estimating the prevalence of centronuclear myopathy.

I Vandersmissen1, V Biancalana2, L Servais3, J J Dowling4, G Vander Stichele1, S Van Rooijen5, L Thielemans6.   

Abstract

Centronuclear myopathies (CNM) are a group of rare inherited muscular disorders leading to a significantly reduced quality of life and lifespan. To date, CNM epidemiologic reports provide limited incidence and prevalence data. Here, an integrated model utilizing available literature is proposed to obtain a better estimate of overall CNM patient numbers by age, causative gene, severity and geographic region. This model combines published epidemiology data and extrapolates limited data over CNM subtypes, resulting in patient numbers related to age and disease subtype. Further, the model calculates a CNM incidence twofold the current estimates. The estimated incidence of 17 per million births for severe X-linked myotubular myopathy (XLMTM), the main subtype of CNM, corresponds to an estimated prevalence of 2715 in the US, 1204 in the EU, 688 in Japan and 72 in Australia. In conclusion, the model provides an estimate of the CNM incidence, prevalence and survival, and indicates that the current estimates do not fully capture the true incidence and prevalence. With rapid advances in genetic therapies, robust epidemiologic data are needed to further quantify the reliability of incidence, prevalence and survival rates for the different CNM subtypes.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Causative gene; Centronuclear myopathy; Geographic region; Incidence; Prevalence; Severity

Mesh:

Year:  2018        PMID: 30122513     DOI: 10.1016/j.nmd.2018.06.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  18 in total

1.  Gene Therapy for Monogenic Inherited Disorders.

Authors:  Janbernd Kirschner; Toni Cathomen
Journal:  Dtsch Arztebl Int       Date:  2020-12-21       Impact factor: 5.594

2.  X-linked myotubular myopathy: A prospective international natural history study.

Authors:  Mélanie Annoussamy; Charlotte Lilien; Teresa Gidaro; Elena Gargaun; Virginie Chê; Ulrike Schara; Andrea Gangfuß; Adele D'Amico; James J Dowling; Basil T Darras; Aurore Daron; Arturo Hernandez; Capucine de Lattre; Jean-Michel Arnal; Michèle Mayer; Jean-Marie Cuisset; Carole Vuillerot; Stéphanie Fontaine; Rémi Bellance; Valérie Biancalana; Ana Buj-Bello; Jean-Yves Hogrel; Hal Landy; Laurent Servais
Journal:  Neurology       Date:  2019-03-22       Impact factor: 9.910

3.  Spectrum of Clinical Features in X-Linked Myotubular Myopathy Carriers: An International Questionnaire Study.

Authors:  Stacha F I Reumers; Frederik Braun; Jennifer E Spillane; Johann Böhm; Maartje Pennings; Meyke Schouten; Anneke J van der Kooi; A Reghan Foley; Carsten G Bönnemann; Erik-Jan Kamsteeg; Corrie E Erasmus; Ulrike Schara-Schmidt; Heinz Jungbluth; Nicol C Voermans
Journal:  Neurology       Date:  2021-05-19       Impact factor: 11.800

Review 4.  Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease.

Authors:  Mo Zhao; Nika Maani; James J Dowling
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis.

Authors:  Robert J Graham; Francesco Muntoni; Imelda Hughes; Sabrina W Yum; Nancy L Kuntz; Michele L Yang; Barry J Byrne; Suyash Prasad; Rachel Alvarez; Casie A Genetti; Tmirah Haselkorn; Emma S James; Laurie B LaRusso; Mojtaba Noursalehi; Salvador Rico; Alan H Beggs
Journal:  Arch Dis Child       Date:  2019-09-04       Impact factor: 3.791

6.  Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy.

Authors:  Eve Fouarge; Arnaud Monseur; Bruno Boulanger; Mélanie Annoussamy; Andreea M Seferian; Silvana De Lucia; Charlotte Lilien; Leen Thielemans; Khazal Paradis; Belinda S Cowling; Chris Freitag; Bradley P Carlin; Laurent Servais
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

Review 7.  From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital Myopathies.

Authors:  Mónika Sztretye; László Szabó; Nóra Dobrosi; János Fodor; Péter Szentesi; János Almássy; Zsuzsanna É Magyar; Beatrix Dienes; László Csernoch
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

Review 8.  Common Pathogenic Mechanisms in Centronuclear and Myotubular Myopathies and Latest Treatment Advances.

Authors:  Raquel Gómez-Oca; Belinda S Cowling; Jocelyn Laporte
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

9.  Myostatin: a Circulating Biomarker Correlating with Disease in Myotubular Myopathy Mice and Patients.

Authors:  Catherine Koch; Suzie Buono; Alexia Menuet; Anne Robé; Sarah Djeddi; Christine Kretz; Raquel Gomez-Oca; Marion Depla; Arnaud Monseur; Leen Thielemans; Laurent Servais; Jocelyn Laporte; Belinda S Cowling
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-04       Impact factor: 6.698

10.  rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy.

Authors:  Jacob A Ross; Hichem Tasfaout; Yotam Levy; Jennifer Morgan; Belinda S Cowling; Jocelyn Laporte; Edmar Zanoteli; Norma B Romero; Dawn A Lowe; Heinz Jungbluth; Michael W Lawlor; David L Mack; Julien Ochala
Journal:  Acta Neuropathol Commun       Date:  2020-10-19       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.